About: DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
Creator	Bailer, Robert Hu, Zonghui Wei, Chih-Jen Mascola, John Bailer, R Enama, Mary Gordon, I Gordon, Ingelise Graham, Barney Koup, R Koup, Richard Ledgerwood, Julie Mascola, J Nabel, G Nabel, Gary Pearce, Melissa Rey, Jeff Tumpey, Terrence Yassine, Hadi Wei, C-J Boyington, C Boyington, J Crnp, Hendel Do, Ledgerwood Hendel, Cynthia Mctamney, P Mctamney, Patrick Pa-C, Enama
Source	Elsevier; Medline; PMC
abstract	Summary Background Because the general population is largely naive to H5N1 influenza, antibodies generated to H5 allow analysis of novel influenza vaccines independent of background immunity from previous infection. We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improve antibody responses to inactivated influenza vaccination. Methods In VRC 306 and VRC 310, two sequentially enrolled phase 1, open-label, randomised clinical trials, healthy adults (age 18–60 years) were randomly assigned to receive intramuscular H5 DNA (4 mg) at day 0 or twice, at day 0 and week 4, followed by H5N1 monovalent inactivated vaccine (MIV; 90 μg) at 4 or 24 weeks, and compared with a two-dose regimen of H5N1 MIV with either a 4 or 24 week interval. Antibody responses were assessed by haemagglutination inhibition (HAI), ELISA, neutralisation (ID80), and immunoassays for stem-directed antibodies. T cell responses were assessed by intracellular cytokine staining. After enrolment, investigators and individuals were not masked to group assignment. VRC 306 and VRC 310 are registered with ClinicalTrials.gov, numbers NCT00776711 and NCT01086657, respectively. Findings In VRC 306, 60 individuals were randomly assigned to the four groups (15 in each) and 59 received the vaccinations. In VRC 310, of the 21 individuals enrolled, 20 received the vaccinations (nine received a two-dose regimen of H5N1 MIV and 11 received H5 DNA at day 0 followed by H5N1 MIV at week 24). H5 DNA priming was safe and enhanced H5-specific antibody titres following an H5N1 MIV boost, especially when the interval between DNA prime and MIV boost was extended to 24 weeks. In the two studies, DNA priming with a 24-week MIV boost interval induced protective HAI titres in 21 (81%) of 26 of individuals, with an increase in geometric mean titre (GMT) of more than four times that of individuals given the MIV-MIV regimen at 4 or 24 weeks (GMT 103–206 vs GMT 27–33). Additionally, neutralising antibodies directed to the conserved stem region of H5 were induced by this prime-boost regimen in several individuals. No vaccine-related serious adverse events were recorded. Interpretation DNA priming 24 weeks in advance of influenza vaccine boosting increased the magnitude of protective antibody responses (HAI) and in some cases induced haemagglutinin-stem-specific neutralising antibodies. A DNA-MIV vaccine regimen could enhance the efficacy of H5 or other influenza vaccines and shows that anti-stem antibodies can be elicited by vaccination in man. Funding National Institutes of Health.
has issue date	2011-12-31(xsd:dateTime)
bibo:doi	10.1016/s1473-3099(11)70240-7
bibo:pmid	21975270
has license	els-covid
sha1sum (hex)	28bbe60a2737d2dbae4aa103f493b46298512829
schema:url	https://doi.org/10.1016/s1473-3099%2811%2970240-7
resource representing a document's title	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
has PubMed Central identifier	PMC7185472
has PubMed identifier	21975270
schema:publication	The Lancet Infectious Diseases
resource representing a document's body	covid:28bbe60a2737d2dbae4aa103f493b46298512829#body_text
is schema:about of	named entity 'vaccination' named entity 'randomised' named entity 'immunogenicity' named entity 'phase' named entity 'VACCINE' named entity 'PHASE 1' named entity 'PREVIOUS' named entity 'ANTIBODIES' named entity 'GENERAL POPULATION' named entity 'DNA' named entity 'INDEPENDENT OF' named entity 'VACCINE' covid:arg/28bbe60a2737d2dbae4aa103f493b46298512829 named entity 'PRIMING' named entity 'IMMUNOGENICITY' named entity 'INFECTION' named entity 'ALLOW' named entity 'BACKGROUND' named entity 'RANDOMISED CLINICAL TRIALS' named entity 'IMMUNOGENICITY' named entity 'DNA' named entity 'VACCINATION' named entity 'INACTIVATED' named entity 'RESPONSES' named entity 'ENCODING' named entity 'VACCINES' named entity 'OPEN LABEL' named entity 'ANTIBODY' named entity 'PRIMING' named entity 'ANALYSIS' named entity 'GENERATED' named entity 'ASSESSED' named entity 'NOVEL' named entity 'IMMUNITY' named entity 'SAFETY' named entity 'LARGELY' named entity 'H5N1' named entity 'antibody' named entity 'antibodies' named entity 'vaccine' named entity 'DNA' named entity 'infl' named entity 'infl' named entity 'general population' named entity 'infection' named entity 'H5N1' named entity 'immunogenicity' named entity 'priming' named entity 'immunogenicity' named entity 'Group 3' named entity 'Good Manufacturing Practices' named entity 'vaccination' named entity 'CD8 T cell' named entity 'inactivated vaccine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software